To the contrary, decreases in blood glucose was almost comparable across age levels in the current study, and Mafa expression increased following luseogliflozin treatment in mice in both the early and late phases of diabetes, leading to improved beta cell function and mass even in mice in the late phase of diabetes. This evidence concerns the gene MAFA and diabetes mellitus.